Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Status:
Recruiting
Trial end date:
2023-11-22
Target enrollment:
Participant gender:
Summary
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for
the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over
a 52 week period. Study participants will continue their established concomitant medications
during participation in this investigation.